Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Research and Innovation Action · Running

LIGAND-AI Protein-ligand data generation at scale to support computational hit finding and optimization

Coordinator
Structural Genomics Consortium Lbg, United Kingdom
Runs
1 November 2025 to 31 October 2030
Status
Running
EU funding
€29.9m
Total cost
€61.2m
Partners
22 organisations in 11 countries
Type
Research and Innovation Action
Grant agreement
101252959

What the project is doing

In the project's own words, from its summary on CORDIS.

The ability to discover and optimize small-molecule ligands by using innovative physics-based, machine learning (ML) and artificial intelligence (AI) approaches would transform and democratize the discovery of new small molecule drugs and related research tools (chemical probes), with important implications for the development of new medicines for rare and pediatric diseases, cancer, and women’s health. The development of these methods is being held back by the lack of high-quality protein-ligand data in the public domain.

To fill this gap, we have assembled a multi-sector public-private partnership that will generate high-quality, ML-ready, open protein-ligand data at scale and as a public good, and will engage with the research community to build, benchmark and test new machine learning models for small molecule discovery and optimization. Our ambition is to identify drug starting points for >500 human proteins and transform and democratize small molecule drug discovery.

Topics

Who is involved

OrganisationCityCountryRole
Structural Genomics Consortium LbgLondonUnited KingdomCoordinator
Universidade Estadual De CampinasCampinas SpBrazilAssociatedpartner
The Hospital for Sick ChildrenTorontoCanadaParticipant
University Health NetworkTorontoCanadaParticipant
HitGen IncChengduChinaAssociatedpartner
Enamine Germany GmbHFrankfurt am MainGermanyParticipant
European Molecular Biology LaboratoryHeidelbergGermanyParticipant
Johann Wolfgang Goethe-Universitaet Frankfurt Am MainFrankfurt Am MainGermanyParticipant
Nuvisan Icb GmbHBerlinGermanyParticipant
Pfizer Pharma GmbHBerlinGermanyAssociatedpartner
Thermo Fisher Scientific (bremen) GmbHBremenGermanyParticipant
Novo Nordisk A/sBagsvaerdDenmarkParticipant
Fundacio Privada Institut D'investigacio Oncologica De Vall-Hebron (vhio)BarcelonaSpainParticipant
Ibm Israel - Science and Technology LtdPetach TikvaIsraelParticipant
Astrazeneca ABSodertaeljeSwedenAssociatedpartner
Chemspace Limited Liability CompanyKyivUkraineParticipant
Abcam LimitedCambridgeUnited KingdomParticipant
Astrazeneca UK LimitedCambridgeUnited KingdomParticipant
Pfizer R&D UK LimitedSandwichUnited KingdomAssociatedpartner
University College LondonLondonUnited KingdomParticipant
Vernalis (r&d) LimitedCambridgeUnited KingdomParticipant
Pfizer IncNew York CityUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI